@article{825c7b0dfbf44e25ac2173ab99969b90,
title = "Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop",
abstract = "Right ventricular dysfunction is a hallmark of advanced pulmonary vascular, lung parenchymal, and left heart disease, yet the underlying mechanisms that govern (mal)adaptation remain incompletely characterized. Owing to the knowledge gaps in our understanding of the right ventricle (RV) in health and disease, the National Heart, Lung, and Blood Institute commissioned a working group to identify current challenges in the field. These included a need to define and standardize normal RV structure and function in populations; access to RV tissue for research purposes and the development of complex experimental platforms that recapitulate the in vivo environment; and the advancement of imaging and invasive methodologies to study the RV within basic, translational, and clinical research programs. Specific recommendations were provided, including a call to incorporate precision medicine and innovations in prognosis, diagnosis, and novel RV therapeutics for patients with pulmonary vascular disease.",
keywords = "cardiovascular disease, hemodynamics, morbidity, prognosis, vascular diseases",
author = "Leopold, {Jane A.} and Kawut, {Steven M.} and Aldred, {Micheala A.} and Archer, {Stephen L.} and Benza, {Ray L.} and Bristow, {Michael R.} and Brittain, {Evan L.} and Naomi Chesler and Deman, {Frances S.} and Erzurum, {Serpil C.} and Gladwin, {Mark T.} and Hassoun, {Paul M.} and Hemnes, {Anna R.} and Tim Lahm and Lima, {Joao A.C.} and Joseph Loscalzo and Maron, {Bradley A.} and {Mercer Rosa}, Laura and Newman, {John H.} and Susan Redline and Stuart Rich and Franz Rischard and Lissa Sugeng and Tang, {W. H.Wilson} and Tedford, {Ryan J.} and Tsai, {Emily J.} and Ventetuolo, {Corey E.} and Youyang Zhao and Aggarwal, {Neil R.} and Lei Xiao",
note = "Funding Information: Dr Aldred reports grants from National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. Dr Benza reports grants from Abbott during the conduct of the study; grants from Actelion, grants from United Therapeutics, grants from Bayer, grants from National Institutes for Health (NIH)/NHLBI outside the submitted work. Dr Chesler reports personal fees from Endotronix, Inc and personal fees from Aria CV outside the submitted work. Dr Gladwin is a coinventor of patents and patent applications directed to the use of recombinant neuroglobin and heme-based molecules as antidotes for carbon monoxide (CO) poisoning, which have been licensed by Globin Solutions, Inc. Dr Gladwin is a shareholder, advisor, and director in Globin Solutions, Inc. Dr Gladwin is also coinventor on patents directed to the use of nitrite salts in cardiovascular diseases, which were previously licensed to United Therapeutics, and are now licensed to Globin Solutions and Hope Pharmaceuticals. Dr Gladwin is a principal investigator in a research collaboration with Bayer Pharmaceuticals to evaluate riociguat as a treatment for patients with sickle cell disease (SCD). Dr Gladwin has served as a consultant for Epizyme, Inc, Actelion Clinical Research, Inc, Accel-eron Pharma, Inc, Catalyst Biosciences, Inc, Modus Therapeutics, Sujana Biotech, LLC, Complexa Inc, Pfizer Inc, and United Therapeutics Corporation. Dr Gladwin is also on Bayer HealthCare LLC{\textquoteright}s Heart and Vascular Disease Research Advisory Board. Dr Hemnes reports personal fees from Actelion, personal fees from Bayer, personal fees from Complexa, personal fees from United Therapeutics, other from PHPrecisionMed, outside the submitted work. Dr Hassoun has served on an advisory board for Merck in 2019. Dr Kawut reports grants from NIH, nonfinancial support from the American Thoracic Society (ATS), and grants from Actelion, United Therapeutics, Gilead, Lung Biotech, Bayer, and Mallinkrodt to the Perelman School of Medicine for continuing medical education (CME) courses. Dr Kawut reports grants and nonfinancial support from Cardiovascular Medical Research and Education Fund and nonfinancial support from Pulmonary Hypertension Association. Dr Kawut has served in an advisory capacity (for grant review and other purposes) for United Therapeutics, Glaxo SmithKline, and Complexa, Inc. without financial support or in-kind benefits. Dr Lahm reports personal fees from Bayer, personal fees from Gilead, personal fees from Actelion, other from Eli Lilly outside the submitted work. Dr Loscalzo is a scientific co-founder of Sci-pher, a startup company that uses network concepts to explore human disease treatment strategies. Dr Maron reports other from Actelion Pharmaceuticals Inc, outside the submitted work. In addition, Dr Maron has a patent US Patent No. 9605047 issued, a patent US Provisional Application ID: 62475955 pending, a patent US Provisional Application Cover Sheet ID: 24624 pending, and a patent US Patent application PCT/US2019/059890 pending. Dr Redline reports grants and personal fees from Jazz Pharmaceuticals, personal fees from RespirCardia Inc outside the submitted work. Dr Tang reports grants from National Institutes of Health, personal fees from Sequana Medical Inc, personal fees from Springer, personal fees from MyoKardia Inc outside the submitted work. Dr Tedford reports other from Actelion, other from Merck, personal fees from United Therapeutics, personal fees from Aria CV, personal fees from Arena pharmaceuticals, personal fees from Gradient, personal fees from Eidos Therapeutics, personal fees and other from Abbott, personal fees and other from Medtronic, personal fees from Itamar, other from Abiomed, and personal fees and other from Acceleron outside the submitted work. Dr Tsai reports grants from NHLBI, grants from American College of Cardiology, grants from The Rachel and Drew Katz Foundation outside the submitted work. In addition, Dr Tsai has a patent Pharmacological Treatment for Right Ventricular Failure (USSN 62/836,315) issued to The Trustees of Columbia University in the City of New York. Dr Ventetuolo reports grants from NHL-BI during the conduct of the study; grants from United Therapeutics, grants from American Thoracic Society, personal fees from Acceleron Pharma, personal fees from Bayer outside the submitted work. The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2021 Lippincott Williams and Wilkins. All rights reserved.",
year = "2021",
month = jun,
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.120.007975",
language = "English (US)",
volume = "14",
pages = "E007975",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "6",
}
